RESULTS:
In mice, time to wound closure was delayed in Nrf2-/-beyond WT (19d vs. 17d), but not as long as K14-CreER-flox or Cdh5-CreER-flox mice (30d), whose phenotype more closely resembled that of db/db (32d). Pathological wound burden was significantly increased in db/db, K14-CreER-flox, and Cdh5-CreER-flox mice as compared to Nrf2-/-and db/db, p<0.0001. Histologic wound analysis revealed that epithelial gap in both K14-CreER-flox (day 7: 8.7mm, day 10: 6.03mm) and Cdh5-CreER-flox (8.55mm, 6.889) mice more closely resembled db/db (10.07mm, 7.55mm), than WT (6.088mm, 4.346) or Nrf2-/-(5.89mm, 5.558mm), p<0.0003. Granulation tissue was with significantly decreased formation in db/ db (.4561mm2), K14CreER-flox (1.083mm2), and Cdh5-CreER-flox (1.873mm2) as compared to WT (4.827mm2) and Nrf2 -/-(2.98mm2) mice, p<0.02. In CD31+ cells within human diabetic wounds, Nrf2 expression was decreased 55% compared to non-diabetic wounds (1.6x10 -6 vs. 1.9x10
-6 corrected total cell fluorescence (CTCF)). Nrf2 expression was slightly decreased in wound-edge keratin-14+ keratinocytes in human diabetic wounds as compared to non-diabetic wounds (7. 2 ) in human diabetic wounds as compared to non-diabetic wounds. Despite more oxidative stress within diabetic wounds as compared to non-diabetic wounds (4.941 ng/mL vs 1.572 ng/mL, p=0.008), expression of Nrf2-downstream anti-oxidant enzyme MnSOD increased 10-fold in nondiabetic wounds, while only a 3-fold increase was seen in diabetic wounds (p<0.001).
CONCLUSION:
Here, we demonstrate that tissue-specific loss of Nrf2 in epithelial and endothelial cells recapitulates the diabetic wound-healing phenotype in mice via impairments in epithelial and endothelial cell function. Furthermore, we demonstrate attenuation of Nrf2 expression and function in endothelial and epithelial cells of human diabetic wounds, resulting in impaired regenerative capacity within wounds. Together, these results implicate Nrf2-associated dysfunction of re-epithelialization and angiogenesis -critical functions of wound healing -in the impaired diabetic phenotype. Our findings further validate the Nrf2-antioxidant pathway as a potential therapeutic target or biomarker for improving pathologic diabetic wound healing. 
